Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck

Fountzilas, George; Skarlos, D.; Athanassiades, A.; Kalogera‐Fountzila, Anna; Samantas, E.; Bacoyiannis, C.; Nicolaou, A.; Dombros, Nikolaos; Briasoulis, Evangelos; Dinopoulou, M.; Stathopoulos, George P.; Pavlidis, Nicholas; Kosmidis, P.; Daniilidis, N.

doi:10.1023/a:1008279503428

Cited by 39 publications

(18 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The response rate in the subset of 35 patients with squamous cell carcinoma was 23%. This is comparable with the activity observed in our study [15]. Similarly, a 39% objective response rate was obtained by Stathopoulos et al [16]among 24 patients treated with paclitaxel 200 mg/m 2 and carboplatin AUC 7.…”

Section: Discussionsupporting

confidence: 93%

Phase II Trial of a Paclitaxel-Carboplatin Combination in Recurrent Squamous Cell Carcinoma of the Head and Neck

Pivot

Cals²,

Cupissol³

et al. 2000

Oncology

View full text Add to dashboard Cite

Objective: Twenty-seven patients with recurrent squamous cell carcinoma of the head and neck were entered in a multicenter study to determine the efficacy of the paclitaxel-carboplatin association. Methods: Standard eligibility criteria applied, i.e. measurable disease, and chemotherapy given as induction treatment or concomitant chemoradiotherapy was allowed if completed more than 6 months prior to the study. Every 21 days, paclitaxel 175 mg/m² and carboplatin AUC 6 were administered. The patient group included 3 females and 24 males with a median age of 61 years (range 39–75 years). Results: All patients were assessable for toxicity and 24 for responses. Main grade 3–4 toxicities were: neutropenia (62.9%), febrile neutropenia (18.5%), anemia (11.1%), thrombocytopenia (14.8%), mucositis (7.4%) and vomiting (7.4%). Among the intent-to-treat population, 29.6% of patients had an objective response, with a median response duration of 4.2 months (range 1–5.7 months). Stable and progressive disease were observed in 11.1 and 48.1% of patients, respectively. The median overall survival was 7.2 months (range 0.5–10.9 months). Conclusion: From these data, paclitaxel-carboplatin seems to have an activity in recurrent squamous cell carcinoma of the head and neck, but the high level of toxicity highlights the need to search for a safer chemotherapy combination.

show abstract

Section: Discussionsupporting

confidence: 93%

Phase II Trial of a Paclitaxel-Carboplatin Combination in Recurrent Squamous Cell Carcinoma of the Head and Neck

Pivot

Cals²,

Cupissol³

et al. 2000

Oncology

View full text Add to dashboard Cite

show abstract

“…Dunphy et al, 9 Stathopoulos et al, 14 and Fountzilas et al 8 reported response rates of 54%, 39%, and 23%, respectively. Of note, however, the report by Dunphy et al 9 included patients with newly diagnosed, previously untreated disease and reported a 60% response rate for patients with nasopharyngeal carcinoma, a highly chemotherapy-sensitive malignancy, but only a 23% response rate for other primary SCCHN.…”

Section: Discussionmentioning

confidence: 97%

“…Stathopoulos et al 14 reported 17% incidence of neutropenic fevers. Fountzilas et al 8 reported only 4% incidence of leukopenia and thrombocytopenia and no neutropenic fevers although their study used G-CSF prophylactically on Days 2-12 of each cycle. Hainsworth et al 15 and Shin 16 report 30% and 21% incidence of neutropenic fever, respectively, a rate similar to that in this report, yet Stathopoulos et al 14 suggest that a third agent may be added with little additional myelotoxicity.…”

Section: Discussionmentioning

confidence: 99%

“…6 Carboplatin a less nephrotoxic and emetogenic platinum analog, has been used in head and neck carcinoma 7 and, in combination with paclitaxel, has significant activity against inoperable SCCHN with reported overall response rates from 23% to 32%. 8,9 In an attempt to improve prior survival rates, we investigated the use of paclitaxel and carboplatin in a limited Phase II study in recurrent or metastatic SC-CHN. The objectives of this Phase II study were to evaluate tumor response to the combination of paclitaxel and carboplatin, time to progression, overall survival in patients treated with this regimen, and qualitative and quantitative toxicities of this regimen.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma

Clark

Hofmeister

Choudhury

et al. 2001

Cancer

View full text Add to dashboard Cite

“…The regimen used in this study was effective at a relative minor cost in terms of toxicity, which should be kept as low as possible in the palliative setting. In particular, Dunphy et al [27], Fountzilas et al [28] and Clark et al [29] reported response rates of 54%, 23% and 27%, respectively, but their series also included chemotherapy-naïve patients and higher doses of carboplatin and paclitaxel. Given these important differences, we reached similar response rates and even superior OS in pretreated patients using lower doses of drugs.…”

Section: Discussionmentioning

confidence: 99%

A phase II study of carboplatin and paclitaxel for recurrent or metastatic head and neck cancer

et al. 2009

View full text Add to dashboard Cite

The aim of this study was to investigate the activity and safety of a regimen containing carboplatin and paclitaxel in patients affected by recurrent or metastatic head and neck cancer. Eligible patients were treated with a 3-week combination of paclitaxel 175 mg/m2 and carboplatin area under the concentration time curve 5 mg/ml/min for a maximum of four cycles. A total of 27 patients entered the study. One patient (3.7%) had a complete response, whereas six patients (22.2%) obtained a partial response. Stable disease was observed in seven patients (25.9%). The disease control rate was 51.8% (95% confidence interval: 32.0-71.3), whereas overall response rate was 25.9% (95% confidence interval: 11.1-46.3). The median overall survival was 8.0 months (range: 2-27), with a 1-year survival of 30.5%. The median progression-free survival was 1.0 month (range: 0-14). Treatment-related deaths or episodes of neutropenic fever were not registered. Grades 3-4 neutropenia was observed in two patients (7.4%), grades 3-4 anaemia and thrombocytopenia in four (14.8%) and one (3.7%) patients, respectively. Nine patients (33.3%) experienced grades 1-2 and one patient (3.7%) grade 3 peripheral neuropathy. The combination of carboplatin and paclitaxel is safe and moderately effective for the treatment of recurrent or metastatic head and neck cancer.

show abstract

Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck

Abstract: The combination of paclitaxel and carboplatin appears to be well tolerated but only moderately active in patients with advanced non-NPC of the head and neck region. However, its activity appears promising in NPC and deserves further investigation.

Cited by 39 publications

References 11 publications

Phase II Trial of a Paclitaxel-Carboplatin Combination in Recurrent Squamous Cell Carcinoma of the Head and Neck

Phase II Trial of a Paclitaxel-Carboplatin Combination in Recurrent Squamous Cell Carcinoma of the Head and Neck

Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma

A phase II study of carboplatin and paclitaxel for recurrent or metastatic head and neck cancer

Contact Info

Product

Resources

About